← Back to Search

T Regulatory Cells

Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells for Acute Respiratory Distress Syndrome (regARDS Trial)

Phase 1
Waitlist Available
Research Sponsored by Jeffrey Bluestone
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days post infusion
Awards & highlights

regARDS Trial Summary

This trial is testing a new treatment for Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, which could potentially reduce lung inflammation, promote lung tissue repair, and significantly improve clinical outcomes.

Eligible Conditions
  • Acute Respiratory Distress Syndrome

regARDS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days post infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days post infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

regARDS Trial Design

3Treatment groups
Experimental Treatment
Group I: cePolyTregs 400 x10^6 cells Open LabelExperimental Treatment1 Intervention
single dose of 400 x 10^6 cells by IV infusion
Group II: cePolyTregs 200 x10^6 cells Open LabelExperimental Treatment1 Intervention
single dose of 200 x 10^6 cells by IV infusion
Group III: cePolyTregs 100 x10^6 cells Open LabelExperimental Treatment1 Intervention
single dose of 100 x 10^6 cells by IV infusion

Find a Location

Who is running the clinical trial?

Jeffrey BluestoneLead Sponsor
1 Previous Clinical Trials
16 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,269 Previous Clinical Trials
5,481,462 Total Patients Enrolled
Immune Tolerance Network (ITN)NETWORK
67 Previous Clinical Trials
7,911 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
Jeffrey Bluestone 2021. "Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05027815.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top